Canton Strategic Holdings (CNTN) Non-Current Debt (2020 - 2025)
Canton Strategic Holdings' (CNTN) quarterly Non-Current Debt came in at $161117.0 in Q3 2025, down 35.48% on a QoQ basis from $249716.0 in Q2 2025.
Powered by 
Analysis
Canton Strategic Holdings (CNTN) Non-Current Debt (2020 - 2025) Analysis & Trends
Canton Strategic Holdings (CNTN) has 2 years of Non-Current Debt data on file, last reported at $161117.0 in Q3 2025.
- Quarterly Non-Current Debt changed N/A year-over-year to $161117.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $161117.0 (changed N/A YoY) and the FY2020 annual result came in at $201737.0, changed N/A from the prior year.
- Non-Current Debt declined to $161117.0 in Q3 2025, from $249716.0 in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $271454.0 in Q1 2025 to a low of $161117.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 591.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 882.16 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 8.96 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Canton Strategic Holdings | 493.37 Mn | 493.37 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | 161,117.00 |
| Jun 30, 2025 | 249,716.00 |
| Mar 31, 2025 | 271,454.00 |
| Dec 31, 2020 | 201,737.00 |